BRENNEN

Industries / Health / Medical supply distribution

Shortages

A shortage is a stretch of weeks or months when a medicine or supply cannot be had in the usual amounts, and makers and distributors decide who gets the stock there is.

4

Milestones achieved, from 1984 to 2024.

2

To watch for: announced, not yet confirmed outside.

2

Open deliverables. Nobody has shipped them.

The road

AchievedWatch forOpen

Achieved

  1. 1984

    Reserve stock by law

    Since 1984 Finland has required drug makers, importers and public hospitals to hold reserve stocks of essential medicines, from two weeks to three, six or ten months of normal use depending on the class of medicine and who holds it; the medicines agency, Fimea, updates the list each year. A 2025 study of 1,910 Finnish shortage notifications from 2021 to 2023 found 1.8 to 2.3 times more shortages among medicines without the duty, and equivalent products ran short 2.5 times as often in Sweden, which has no such duty. The direct cost was 1.7 to 4.4 million euros a year from 2019 to 2023.

    pmc.ncbi.nlm.nih.gov

    Credit

    the Finnish state; study by Reko Ravela, Timi Aaltonen and colleagues

  2. 2012

    Shortage drugs leak out

    After a 2011 executive order told the FDA to pass to the Justice Department any finding that shortages led sellers to hoard drugs or charge "exorbitant prices", congressional staff traced 300 distribution chains for five short-supply injectable drugs through 125 companies. In 69% of the chains the drugs left the usual route from maker to wholesaler to hospital through pharmacies that resold them to "gray market" wholesalers, and units normally costing $10 to $20 were marked up to $200 or more; one hospital paid $600 a vial for a chemotherapy drug that a pharmacy had bought for $7.

    Lessonthe leak could be followed only because each resale carried a pedigree.

    oversightdemocrats.house.govgovinfo.gov

    Credit

    staff of Senators John D. Rockefeller IV and Tom Harkin and Representative Elijah E. Cummings; the White House, in Executive Order 13588

  3. 2020

    Free flights, no map

    In the first months of COVID-19 the US government chose not to buy personal protective equipment (PPE) such as masks and gowns itself. Under Project Airbridge it paid for flights bringing in PPE bought by six distributors, Cardinal Health, Concordance Healthcare Solutions, Henry Schein, McKesson, Medline and Owens & Minor. They were told to deliver half of it "across the customer base in the hotspot", with little guidance on who needed it most and none on the other half, and the contracts did not require them to report prices.

    Lessonpaying to move stock faster did not decide who got it.

    oversightdemocrats.house.gov

    Credit

    the federal government's Project Airbridge and the six distributors; findings from the House Oversight Committee's memo of 2 July 2020

  4. 2024

    One plant, rationed supply

    Hurricane Helene shut Baxter's North Cove plant in Marion, North Carolina, on 29 September 2024; it made about 60% of the US supply of IV solutions, by the American Hospital Association's count. Baxter rationed by allocation, a share of each customer's orders from March to August 2024: at first 40% for hospitals buying direct and 10% for distributors, because it believed many distributors had product in storage, then 60% for both from 9 October.

    Lessondamage to one plant set how much IV fluid every US hospital could order.

    healthcaredive.commhaonline.orgdebbiedingell.house.gov

    Credit

    Baxter; the US Department of Health and Human Services, which asked makers, wholesalers and distributors to review their allocations

Watch for

  1. EU rules for critical medicines

    On 12 May 2026 the European Parliament and the Council of the EU reached a provisional agreement on a Critical Medicines Act. Public buyers of critical medicines would have to weigh supply resilience in tenders, five member states instead of nine could ask the Commission to buy on their behalf, and sharing information on national contingency stocks would stay voluntary. EMA is already assessing supply-chain weak points for medicines on the Union list of critical medicines, first published in December 2023.

    Achieved whenthe act is published in the Official Journal and applies, and the first joint purchase or reallocation of stock under it is reported.

    mccannfitzgerald.comema.europa.eu

    Claimed by

    the Parliament and Council negotiators, May 2026, as reported by the law firm McCann FitzGerald

  2. Germany's six-month stock rule

    Since July 2023 German law has required drug makers that win the statutory insurers' rebate contracts to hold six months of expected demand. BfArM, the federal medicines institute, counted 1,017 shortage reports in 2023 and 892 in 2024. TK, a large statutory insurer, inspected the stores of six of its contract suppliers, found the minimum stock about 80% met, and says supply has clearly eased since the law; the insurers' association's evaluation, reported in January 2026, found the law had little effect.

    Achieved whenBfArM's evaluation, or an independent study that compares medicines the rule covers with ones it does not, finds fewer shortages that can be put down to the rule.

    tk.depharmazeutische-zeitung.depharmazeutische-zeitung.de

    Claimed by

    TK, in its Lieferklima-Report 2025, November 2025

Open

  1. 01

    Shortage forecasts filed early

    A forecast of which US drugs will go into shortage in the next six months, made only from public data and posted with a date before the outcome is known, then scored when the six months are up against a simple rule (for example, sterile injectables with several old generic makers).

    The brief
    Credit · unclaimed
  2. 02

    Germany's stock rule, checked

    An after-the-fact test of the German law passed on 23 June 2023 that set a six-month stock duty for off-patent drugs sold under rebate contracts. Compare monthly shortage reports for off-patent generics, which the rule mostly covers, and patented drugs, which it does not, in the federal medicines institute's (BfArM's) public database from 2019 to now, before and after the rule.

    The brief
    Credit · unclaimed

Open 01 · the brief

Shortage forecasts filed early

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A forecast of which US drugs will go into shortage in the next six months, made only from public data and posted with a date before the outcome is known, then scored when the six months are up against a simple rule (for example, sterile injectables with several old generic makers).

Why it is still open

Published models are scored on the past. M. Pall and colleagues predicted shortage levels in Canada one month ahead from 22 pharmacies' sales, with 69% accuracy; a 2026 analysis of about 3,000 US drugs from FDA and ASHP data found machine learning added little over a simple scoring rule and said it "does not establish whether the models can reliably identify drugs that will enter shortage in the future". For Canada, a portfolio project on GitHub, PickettAnalytics' drug-shortage-forecast, posted top-25 lists for February to April 2026 and scored them in October against Health Canada's records; its author notes that only April's outcomes were wholly unseen when its list was made. No dated forecast for every US drug has been posted and scored.

github.compmc.ncbi.nlm.nih.govpharmacytimes.com

Built with what exists

openFDA's drug shortages endpoint, which held 1,578 records on 20 November 2026; FDA's NDC directory and recall records, also on openFDA; Python with scikit-learn; an AI model that returns probabilities for many fixed-answer questions at once, such as Gemini Decision 1 (see the Note "A thousand questions, one pass"; its accuracy figures are Google's own).

api.fda.gov

  1. First step

    Download the shortage records, find the drugs that entered shortage in the first half of 2026, and check how many a three-feature rule would have flagged from data available on 1 January 2026.

  2. Done looks like

    two rounds of forecasts posted publicly with timestamps, each giving a probability for every drug in scope; after six months, the Brier score (the average squared gap between forecast and outcome) and the share of new shortages flagged in advance, for the model and for the simple rule.

Open 02 · the brief

Germany's stock rule, checked

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

An after-the-fact test of the German law passed on 23 June 2023 that set a six-month stock duty for off-patent drugs sold under rebate contracts. Compare monthly shortage reports for off-patent generics, which the rule mostly covers, and patented drugs, which it does not, in the federal medicines institute's (BfArM's) public database from 2019 to now, before and after the rule.

Why it is still open

The reviews written so far disagree and come from interested parties. The law asked the statutory insurers' association (GKV-Spitzenverband) and BfArM for evaluations by 31 December 2025; the insurers' report, as reported in January 2026, found the law had raised spending on short-supply drugs by €100 million a year without adding deliveries, while an analysis by the IGES institute for Pro Generika, the generic makers' association, found total shortages down only slightly and those of supply-critical ingredients up, and TK, an insurer, describes supply as clearly easier after inspecting six suppliers' stores. None was found with data and code that someone else can rerun. Beyond these, the evidence is a model and a neighbor. A 2026 study by Afschin Gandjour used BfArM's records up to May 2023 to estimate that a six-month reserve could prevent about 70% of shortages, a projection made before the rule could be observed; a 2025 study found fewer shortages for medicines under Finland's storage duty. Medicines for Europe, which speaks for makers of off-patent medicines, says claims that stockpiling reduces shortages "are not supported by evidence".

pharmazeutische-zeitung.depharmazeutische-zeitung.deprogenerika.depmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.govmedicinesforeurope.com

Built with what exists

BfArM's shortage database, linked from its shortages page; Python with pandas and statsmodels for the before-and-after comparison; a language model to match product names to active ingredients and patent status.

bfarm.de

  1. First step

    Export BfArM's list and count reports per month for ten common generic ingredients and ten patented ones.

  2. Done looks like

    monthly counts for both groups from January 2019 to the latest month; the estimated change after the rule with its confidence interval; the same test repeated for the shortages BfArM classes as clinically relevant; code and data published so anyone can rerun it.